馥感林口服液联合匹多莫德治疗儿童反复呼吸道感染疗效观察

摘要

Objective:To evaluate the efficacy and adverse reactions of fuganlin oral liquid and pidotimod in treatment of repeated respiratory tract infections(RRTI)in children. Methods:All 168 patients with RRTI were randomly divided into ob-servation group A(42 cases),control Group A,B and C( each 42 cases of group). Group A were treated with fuganlin oral liquid,Group B were treated with pidotimod oral solution. Group C were treated with anti - infective and symptomatic treat-ment. The observation group were treated with fuganlin oral liquid and pidotimod. The fever time and clinical signs were ob-served. Within 1 year frequency of respiratory infection were statistically analyzed. Results:The time of back to normal body temperature,symptoms in observation group improved significantly shortened compared with control group B and C(P < 0. 05). The frequency of respiratory infection within 1 year ,observation group decline significantly than the control group A and C (P < 0. 05). Conclusion:Fuganlin oral liquid and pidotimod is effective and safe in treatment of repeated respiratory tract in-fections in children.%目的：探讨馥感林口服液联合匹多莫德治疗儿童反复呼吸道感染（ RRTI）的疗效及不良反应。方法：将2012年8月—2014年2月儿科门诊就诊的 RRTI 患儿168例，随机分为观察组和对照 A，对照 B，对照 C 三组，每组各42例。对照 A 组给予馥感啉口服液，对照 B 组给予匹多莫德口服液，对照 C 组常规抗感染对症治疗，观察组给予馥感林口服液联合匹多莫德治疗。对各组患儿发热时间、临床症状进行比较并随访观察1年，对服药后1年内呼吸道感染发作次数进行统计学分析。结果：观察组热退、症状改善时间较对照 B 组及对照 C 组明显缩短（P ＜0.05）。停药后1年内呼吸道感染次数，观察组较对照 A 组及对照 C 组明显下降，差异有统计学意义（P ＜0.05）。结论：馥感啉口服液联合匹多莫德口服液治疗及预防反复呼吸道感染疗效确切，安全性较好。